Secondary analysis of VIVID-1 in moderately-to-severely active Crohn's disease: mirikizumab beat placebo for histologic response and remission at week 12, with rates similar to ustekinumab, and gave greater histologic response than ustekinumab at week 52.
Secondary analysis
Jairath et al. Histologic and combined histologic-endoscopic outcomes with mirikizumab in Crohn's disease: VIVID-1 trial results